Off-label studies on apremilast in dermatology: a review.
CONCLUSION: The relatively safe adverse effect profile of apremilast and its broad immunomodulatory characteristics may make it a promising option in the future for patients with difficult to treat diseases in dermatology, refractory to first line therapies, but further studies will be necessary to clarify its role.
PMID: 30935262 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
More News: Alopecia | Alopecia Areata | Arthritis | Databases & Libraries | Dermatitis | Dermatology | Hidradenitis | Psoriasis | Psoriatic Arthritis | Rheumatology | Skin | Study